Finance

Lists
Why is IONS up 2.77%?
Dive Deeper
IONS:NASDAQ
Ionis Pharmaceuticals Inc
$44.13
+2.77%
(+1.19) 1D
Oct 19, 2:45:26 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IONS...
Open
$43.33
High
$44.21
Low
$43.00
Mkt. cap
7.33B
Avg. vol.
3.97M
Volume
1.05M
52-wk high
$86.74
52-wk low
$42.08
EPS
-$3.47
Beta
0.38
Shares outstanding
166.18M
No. of employees
1K
Open
$43.33
High
$44.21
Low
$43.00
Mkt. cap
7.33B
Avg. vol.
3.97M
Volume
1.05M
52-wk high
$86.74
52-wk low
$42.08
EPS
-$3.47
Beta
0.38
Shares outstanding
166.18M
No. of employees
1K
News stories
From web sources and news partners
Profile
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015. Wikipedia
About Ionis Pharmaceuticals Inc
CEOBrett P. Monia Ph.D.
Employees1.48K
Founded1989
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websiteionis.com
Analyst ratings
Based on 20 analysts giving stock ratings to IONS in the past 3 months
Strong buy
Buy
17
Hold
3
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for IONS in the last 3 months.
Highest
Current $44.13
$104.00 (+135.67%)
Average
$83.89 (+90.10%)
Lowest
$54.00 (+22.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joon Lee
UBS
Buy
Upgraded
$88.00
+99.4%
10/16/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$100.00
+126.6%
10/08/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$91.00
+106.2%
10/09/2026
Luca Issi
RBC Capital
Buy
Maintained
$85.00
+92.6%
10/08/2026
David Lebowitz
BMO Capital
Hold
Maintained
$54.00
+22.4%
09/23/2026
Justin Kim
Oppenheimer
Buy
Maintained
$85.00
+92.6%
09/24/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$84.00
+90.3%
09/23/2026
Joseph Stringer
Needham
Buy
Maintained
$86.00
+94.9%
09/23/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
$85.00
+92.6%
09/24/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/22/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$70.00
+58.6%
09/22/2026
Eliana Merle
Barclays
Buy
Maintained
$85.00
+92.6%
09/18/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$80.00
+81.3%
09/14/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$56.00
+26.9%
09/14/2026
Tiago Fauth
Raymond James
Buy
Maintained
$84.00
+90.3%
09/08/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$104.00
+135.7%
09/09/2026
Eric Joseph
Citi
Buy
Maintained
$100.00
+126.6%
09/04/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$60.00
+36%
08/19/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$94.00
+113%
08/17/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$95.00
+115.3%
08/14/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$95.00
+115.3%
08/14/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$68.00
+54.1%
08/02/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
07/15/2026
Akash Tewari
Jefferies
Buy
Maintained
$90.00
+103.9%
07/15/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$106.00
+140.2%
06/05/2026
Unknown Analyst
Citi
Buy
Initiated
$115.00
+160.6%
05/15/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$110.00
+149.3%
04/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
$104.00
+135.7%
04/10/2026
Next call in 9 days
Wed, Oct 28, 5:30 PM
Fiscal period
Q3 2026
- / -$0.92
Revenue / Est. (USD)
- / 186.53M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
156.72M
203.33M
246.09M
267.95M
Cost of goods sold
220.09M
287.60M
213.16M
208.75M
Cost of revenue
220.09M
287.60M
213.16M
208.75M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
96.81M
130.19M
150.36M
160.60M
Operating expense
96.81M
130.19M
150.36M
161.50M
Total operating expenses
316.90M
417.79M
363.52M
370.24M
Operating income
-160.18M
-214.46M
-117.42M
-102.29M
Other non operating income
363.00K
57.00K
-456.00K
987.00K
EBT including unusual items
-128.39M
-227.92M
-92.31M
-113.38M
EBT excluding unusual items
-158.30M
-212.36M
-114.89M
-103.20M
Income tax expense
213.00K
1.48M
218.00K
1.26M
Effective tax rate
-0.17%
-0.65%
-0.24%
-1.11%
Other operating expenses
-
-
-
900.00K
Net income
-128.61M
-229.39M
-92.53M
-114.65M
Net profit margin
-82.06%
-112.82%
-37.60%
-42.79%
Earnings per share
-0.61
-1.15
-0.30
-0.42
Interest and investment income
23.68M
24.73M
25.48M
20.23M
Interest expense
-22.16M
-22.69M
-22.50M
-22.12M
Net interest expenses
1.52M
2.04M
2.99M
-1.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
-157.31M
-210.56M
-113.46M
-98.16M
Gain or loss from assets sale
-3.94M
638.00K
40.00K
441.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps